

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

**FORM 10-K/A
(Amendment No. 1)**

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2017

OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION
PERIOD FROM TO

Commission File Number 001-37906

AVISTA HEALTHCARE PUBLIC ACQUISITION CORP.

(Exact name of Registrant as specified in its Charter)

Cayman Islands
(State or other jurisdiction of
incorporation or organization)
65 East 55th Street
18th Floor
New York, New York
(Address of principal executive offices)

98-1329150
(I.R.S. Employer
Identification No.)

10022
(Zip Code)

Registrant's telephone number, including area code: **(212) 593-6900**

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Name of each exchange on which registered</u>
Units, each consisting of one Class A ordinary share, \$0.0001 par value, and one Warrant to purchase one half of one Class A ordinary share	NASDAQ Capital Market
Class A ordinary shares, par value \$0.0001 per share	NASDAQ Capital Market
Warrants to purchase Class A ordinary shares	NASDAQ Capital Market

Securities registered pursuant to Section 12(g) of the Act:

None

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES NO

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES NO

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES NO

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). YES NO

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405) is not contained herein, and will not be contained, to the best of Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer
(Do not check if a
smaller reporting company)

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 of the Exchange Act.

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES NO

As of June 29, 2018, the last business day of the Registrant's most recently completed second fiscal quarter the aggregate of the Registrant's Class A ordinary shares outstanding held by non-affiliates of the Registrant was approximately \$310,930,000 based on its last reported sales price of \$10.03 on the NASDAQ Capital Market.

At December 31, 2017, there were 31,000,000 Class A ordinary shares, \$0.0001 par value, and 7,750,000 Class B ordinary shares, \$0.0001 par value, issued and outstanding.

Documents Incorporated by Reference: Portions of the proxy statement that was filed with the Commission on May 31, 2018 in connection with the 2018 annual meeting of shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K/A.

EXPLANATORY NOTE

Avista Healthcare Public Acquisition Corp. (the “Company”) is filing this Amendment No. 1 on Form 10-K/A to amend its Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission (“SEC”) on March 14, 2018 (the “2017 Annual Report”) solely to include language inadvertently omitted from the previously filed Exhibits 31.1 and 31.2, and contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are attached hereto. This Amendment should be read in conjunction with the Company’s 2017 Annual Report and other Company filings made with the SEC.

Except as described above, no other changes have been made to the 2017 Annual Report, and this Form 10-K/A does not modify, amend or update in any way any of the financial or other information contained in the 2017 Annual Report. This Form 10-K/A does not reflect events that may have occurred subsequent to the filing date of the 2017 Annual Report.

PART IV

Item 15. Exhibits, Financial Statement Schedules.

b) Exhibits:

<u>Exhibit Number</u>	<u>EXHIBITS Description</u>
2.1**	<u>Transaction Agreement, dated August 21, 2017, by and among Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc., Avista Healthcare NewCo, LLC and Envigo International Holdings, Inc. (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed on August 22, 2017).</u>
2.2**	<u>Amendment No. 1 to the Transaction Agreement, dated as of November 22, 2017, by and among Avista Healthcare Public Acquisition Corp., Envigo International Holdings, Inc., Avista Healthcare Merger Sub, Inc. and Avista Healthcare NewCo, LLC (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K of Avista Healthcare Public Acquisition Corp., filed with the SEC on November 22, 2017).</u>
2.3**	<u>Amendment No. 2 to the Transaction Agreement, dated as of December 22, 2017, by and among Avista Healthcare Public Acquisition Corp., Envigo International Holdings, Inc., Avista Healthcare Merger Sub, Inc. and Avista Healthcare NewCo, LLC (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K of Avista Healthcare Public Acquisition Corp., filed with the SEC on December 26, 2017).</u>
2.4**	<u>Amendment No. 3 to the Transaction Agreement, dated as of January 21, 2018, by and among Avista Healthcare Public Acquisition Corp., Envigo International Holdings, Inc., Avista Healthcare Merger Sub, Inc. and Avista Healthcare NewCo, LLC (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K of Avista Healthcare Public Acquisition Corp., filed with the SEC on January 22, 2018).</u>
2.5**	<u>Amendment No. 4 to the Transaction Agreement, dated as of February 9, 2018, by and among Avista Healthcare Public Acquisition Corp., Envigo International Holdings, Inc., Avista Healthcare Merger Sub, Inc. and Avista Healthcare NewCo, LLC (incorporated by reference to Exhibit 2.5 to the Current Report on Form S-4/A of Avista Healthcare Public Acquisition Corp., filed with the SEC on February 9, 2018).</u>
2.6**	<u>Mutual Termination Agreement, dated February 14, 2018, by and among Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc., Avista Healthcare NewCo, LLC and Envigo International Holdings, Inc. (incorporated by reference to Exhibit 2.6 to the 10-K of Avista Healthcare Public Acquisition Corp., filed with the SEC on March 14, 2018).</u>
3.1**	<u>Amended and Restated Memorandum and Articles of Association (incorporated by reference to Exhibit 3.1 filed to the Company’s current report on Form 8-K filed by the Registrant on October 14, 2016).</u>

- 4.1** [Specimen Unit Certificate \(incorporated by reference to Exhibit 4.1 filed with the Form S-1 filed by the Registrant on September 2, 2016\).](#)
- 4.2** [Specimen Class A Ordinary Share Certificate \(incorporated by reference to Exhibit 4.2 filed with the Form S-1 filed by the Registrant on September 2, 2016\).](#)
- 4.3** [Specimen Warrant Certificate \(incorporated by reference to Exhibit 4.3 filed with the Form S-1 filed by the Registrant on September 2, 2016\).](#)
- 10.1** [Warrant Agreement, dated as of October 10, 2016, between the Company and Continental Stock Transfer & Trust Company, as warrant agent \(incorporated by reference to Exhibit 4.4 filed to the Company's current report on Form 8-K filed by the Registrant on October 14, 2016\).](#)
- 10.2** [Letter Agreement, dated October 10, 2016, among the Company, its officers and directors and Avista Acquisition Corp. \(incorporated by reference to Exhibit 10.1 filed to the Company's current report on Form 8-K filed by the Registrant on October 14, 2016\).](#)
- 10.3** [Investment Management Trust Agreement, dated as of October 10, 2016, between the Company and Continental Stock Transfer & Trust Company, as trustee \(incorporated by reference to Exhibit 10.2 filed to the Company's current report on Form 8-K filed by the Registrant on October 14, 2016\).](#)
- 10.4** [Registration Rights Agreement, dated as of October 10, 2016, among the Company, Avista Acquisition Corp. and certain other security holders named therein \(incorporated by reference to Exhibit 10.3 filed to the Company's current report on Form 8-K filed by the Registrant on October 14, 2016\).](#)
- 10.5** [Administrative Services Agreement, dated October 10, 2016, between the Company and Avista Capital Holdings, L.P. \(incorporated by reference to Exhibit 10.5 filed to the Company's current report on Form 8-K filed by the Registrant on October 14, 2016\).](#)
- 10.6** [Private Placement Warrants Purchase Agreement dated as of October 10, 2016, among the Company, Avista Acquisition Corp. and certain other purchasers named therein \(incorporated by reference to Exhibit 10.4 filed to the Company's current report on Form 8-K filed by the Registrant on October 14, 2016\).](#)
- 10.7** [Form of Indemnity Agreement \(incorporated by reference to Exhibit 10.7 filed with the Form S-1 filed by the Registrant on September 2, 2016\).](#)
- 10.8** [Promissory Note, dated September 1, 2016, issued to Avista Acquisition Corp. \(incorporated by reference to Exhibit 10.1 filed with the Form S-1 filed by the Registrant on September 2, 2016\).](#)
- 10.9** [Securities Subscription Agreement, dated December 14, 2015, between the Registrant and Avista Acquisition Corp. \(incorporated by reference to Exhibit 10.5 filed with the Form S-1 filed by the Registrant on September 2, 2016\).](#)
- 10.10** [Parent Sponsor Letter Agreement, dated August 21, 2017, by and among Avista Healthcare Public Acquisition Corp., Avista Acquisition Corp., and certain individuals \(incorporated by reference to Exhibit 10.10 to the Registrant's Current Report on Form 8-K filed on August 22, 2017\).](#)
- 24.1** [Power of Attorney \(incorporated by reference to Exhibit 24.1 to the 10-K of Avista Healthcare Public Acquisition Corp., filed with the SEC on March 14, 2018\).](#)
- 31.1* [Certification of Principal Executive Officer Pursuant to Rules 13a-14\(a\) and 15d-14\(a\) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](#)
- 31.2* [Certification of Principal Financial Officer Pursuant to Rules 13a-14\(a\) and 15d-14\(a\) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](#)
- 32.1** [Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 \(incorporated by reference to Exhibit 32.1 to the Company's Annual Report on Form 10-K filed with the SEC on March 14, 2018\).](#)
-

32.2**	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 32.2 to the Company's Annual Report on Form10-K filed with the SEC on March 14, 2018).
101.INS**	XBRL Instance Document (incorporated by reference to Exhibit 101.INS to the 10-Q of Avista Healthcare Public Acquisition Corp., filed with the SEC on March 14, 2018).
101.SCH**	Taxonomy Extension Schema Document (incorporated by reference to Exhibit 101.SCH to the 10-Q of Avista Healthcare Public Acquisition Corp., filed with the SEC on March 14, 2018).
101.CAL**	Taxonomy Extension Calculation Linkbase Document (incorporated by reference to Exhibit to the 10-Q of Avista Healthcare Public Acquisition Corp., filed with the SEC on March 14, 2018).
101.DEF**	Taxonomy Extension Definition Linkbase Document (incorporated by reference to Exhibit 101.DEF to the 10-Q of Avista Healthcare Public Acquisition Corp., filed with the SEC on March 14, 2018).
101.LAB**	Taxonomy Extension Label Linkbase Document (incorporated by reference to Exhibit 101.LAB to the 10-Q of Avista Healthcare Public Acquisition Corp., filed with the SEC on March 14, 2018).
101.PRE**	Taxonomy Extension Label Linkbase Document (incorporated by reference to Exhibit 101.PRE to the 10-Q of Avista Healthcare Public Acquisition Corp., filed with the SEC on March 14, 2018).

* Filed herewith.

** Previously filed.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AVISTA HEALTHCARE PUBLIC ACQUISITION CORP.

Date: October 15, 2018

By: /s/ David Burgstahler

David Burgstahler
President and Chief Executive Officer
(Principal Executive Officer)

Date: October 15, 2018

By: /s/ John Cafasso

John Cafasso
Chief Financial Officer

**CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, David Burgstahler, certify that:

1. I have reviewed this Annual Report on Form 10-K/A of Avista Healthcare Public Acquisition Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Date: October 15, 2018

/s/ David Burgstahler

David Burgstahler
President and Chief Executive Officer

**CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, John Cafasso, certify that:

1. I have reviewed this Annual Report on Form 10-K/A of Avista Healthcare Public Acquisition Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Date: October 15, 2018

/s/ John Cafasso

John Cafasso
Chief Financial Officer
